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Introduction
Porcine circovirus 2 (PCV2) is a small, non-enveloped virus with a single-stranded circular DNA genome and the causative agent of Porcine circovirus-associated disease (PCVAD) (Tischer et al., 1982; Allan et al., 2000) . PCVAD is associated with a number of manifestations, including postweaning multisystemic wasting syndrome Abbreviations: CP, capsid protein; CSVB5, Coxsackie virus B5; Cterminus, carboxyl-terminus; DMEM, Dulbecco's modified Eagle medium; ECL, enhanced chemiluminescence; iELISA, indirect enzyme-linked immunosorbent assay; IFA, immunofluorescence assay; KLH, keyhole limpet hemocyanin; LPBI, liquid phase blocking immunoassay; mAb, monoclonal antibody; ORFs, open reading frames; PBST, PBS containing 0.05% Tween 20; PCV, porcine circovirus; PCV1, porcine circovirus type 1; PCV2, porcine circovirus type 2; PDNS, porcine dermatitis and nephropathy syndrome; PEG, polyethylene glycol; PMWS, postweaning multisystemic wasting syndrome; SCF, suspending cells were fixed; SPF, specific pathogen free; TRITC, tetramethyl rhodamine isothiocyanate; VLP, virus-like particle.
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(PMWS), porcine dermatitis and nephropathy syndrome (PDNS), respiratory disease, enteritis, and reproductive failure (Allan et al., 1998; Segalés, 2012; Chae, 2005; Opriessnig et al., 2007) . Therefore, PCV2 is recognized as an endemic infection of swine, worldwide, and one of the most economically important infectious agents in modern swine production (Opriessnig et al., 2007) . Since all of commercial vaccines contain the PCV2a capsid protein as the major immunogen, it might cause PCV2 to have a dramatic global genotype shift from PCV2a to PCV2b around 2003 (Patterson and Opriessnig, 2010; Beach and Meng, 2012) and PCV2b now seems as the predominant genotype (Trible and Rowland, 2012) .
PCV2 contain 11 open reading frames (ORFs) (Hamel et al., 1998) . ORF1 and ORF2 genes are the two major ORFs and orientated in opposite directions. ORF1 encodes for the non-structural replicase proteins Rep and Rep' (Hamel et al., 1998; Cheung, 2003) . The structural capsid protein (CP) is encoded by ORF2 (Hamel et al., 1998; Nawagitgul et al., 2000; Huang et al., 2011) . According to the classification system of previous studies (Olvera et al., 2007; Segalés et al., 2008; Saha et al., 2012) , PCV2 strains were defined as two subgroups with eight clusters: PCV2b-1A to PCV2b-1C and PCV2a-2A to PCV2a-2E. Recently, some CP peptides are proved to be immunorel- Non-conserved amino acids are bold and underline. C3 was appended with a N-terminal cysteine during synthesis, which was required for conjugation with maleimide-activated carriers.
evant epitopes for virus type discrimination. The identification of antigenic domains in the PCV2 CP (residues 65-87, 113-139 and 193-207) were determined exclusively by PEPSCAN analysis (Mahé et al., 2000) . In another study, PCV1/PCV2 chimeric viruses and PCV2 monoclonal antibodies (mAbs) were used to map the antigenic epitopes of the PCV2 CP (Lekcharoensuk et al., 2004) . The results revealed at least five different but overlapping conformational epitopes within residues 47-63, 165-200 and 230-233 of the PCV2a CP. Further studies found linear B-cell epitopes within the residues 156-162, 175-192, 195-202, and 231-233 of the PCV2b CP that were finely defined with synthetic peptides and mAbs (Shang et al., 2009) . It was indicated that the conformational epitope composed of the motif the residues 231-233 and 1-60 together (Shang et al., 2009 ). The crucial residues 59, 63, 83, 130, 133, 206 , 210 of PCV2 CP are responsible for the differential reactivity of mAbs to different PCV2 strains (Saha et al., 2012) . Based on previous studies, there are lots of epitopes on Cterminus of PCV2 CP. It would be facile to generate antibodies by utilizing Cterminus of PCV2 CP. We pretested immunoreactivities of synthetic peptides with sera from PCV2-infected pigs. These data showed swine sera reacted well with the peptide (C3) of the Cterminus of the PCV2b CP (submitted for publication). Here, we explored the C3 could be a candidate of immunogen involved during humoral immunity. To demonstrate the C3 can mimic the epitopes present on the native PCV2 CP, we utilized the conjugated C3-KLH to inoculate mice and generate mAbs. We have generated 8 mAbs and defined their minimal binding region on PCV2 CP using epitope mapping and liquid phase blocking immunoassay. Our studies discover the importance of fine epitopes on the Cterminus of the PCV2b CP and character of mAbs.
Materials and methods

Design of synthesized peptides
Peptides were synthesized by the solid-phase peptide synthesis method using a ThuraMed Tetras106 Peptide Synthesizer (CreoSalus, USA). Peptide purity was assessed by high performance liquid chromatography (LC-10ATVP serial dual plunger pump, Shimadzu, USA) and were tested for the correct mass by Waters Micromass ZQ TM 2000 LC Mass Spectrometer (Waters, USA). All synthetic peptides used in the study were synthesized by the YaoHong Biotechnology Inc. (New Taipei, Taiwan) and listed in Table 1 . The C3 was appended with an N-terminal cysteine during synthesis, which was required for conjugation with maleimide-activated carriers. In order to induce specific antibodies against the C3, the C3 was conjugated to the carrier protein keyhole limpet hemocyanin (KLH) using heterobifunctional cross-linker Sulfo-SMCC (Thermo scientific, USA).
Generation of mAbs against the capsid peptide (C3)
Four five-week-old, female, BALB/cByJNarl mice were purchased from a specific pathogen free (SPF) colony (the National Applied Research Laboratories, Taiwan). SPF status was verified by bacteriology, parasitology, histopathology, serology, and genetic testing through the supplier and no specific pathogens were detected. Mice were maintained in isolation rooms in filtertop cages and the room temperature was at 20-27 • C. Mice were fed with a commercially pelleted diet (rodent chow), and clean water free from bacterial or chemical contamination was available ad libitum. This study follow the standards of the Guide of the Care and Use of Laboratory Animals and the study protocol was approved by tide immunogen in incomplete Freund's adjuvant (Sigma-Aldrich, USA). Each mouse was injected intraperitoneally with 20 g of the peptide alone in PBS on different day after last booster. Euthanasia was performed 3 days later of last injection and the spleen was collected. Splenocytes were fused with the myeloma cell line Sp2/0 using 50% polyethylene glycol 1500 (Roche, Penzberg, Germany). The fused cells were cultured with Dulbecco's modified Eagle medium (DMEM) containing hypoxanthine-aminoprerinthymidine. Resulting hybridoma cells were maintained in DMEM medium containing hypoxanthine-thymidine and were cloned by limiting dilution. Hybridoma supernatants were screened for the presence of peptide-specific antibodies by indirect ELISA. Estab- lished clones were injected intraperitoneally into pristane-primed BALB/cByJNarl mice (5 × 10 5 cells/mouse). The ascites containing mAbs were collected 9-17 d post injection and purified.
Isotyping of mAb
The isotype of the produced mAbs was determined using a SBA ClonotypingTM System/HRP (Southern Biotechnology, Birmingham, AL, USA). This test identifies the IgG1, IgG2a, IgG2b, IgG3, IgA and IgM isotype classes and the and type of the light chain using monospecific goat pAbs. A sandwich immunoenzyme assay was performed according to the manufacturer's instructions. Briefly, Ninety-six microtiter plates were coated overnight at 4 • C with 100 l (10 g/ml) per well of anti-mouse Ig (H + L). After three washes with PBS containing 0.05% Tween 20 (PBST), the coated plates were blocked for 1 h at 37 • C with PBST containing 5% casein hydrolysate. After washing, subsequently incubated for 2 h at 37 • C with 100 l per well of undiluted hybridoma supernatant. After washing, 100 l of PBST, HRP labeled goat anti-mouse IgG1, −IgG2a, −IgG2b, −IgG3, −IgA, −IgM, -light chain, and -light chain were each added to a well. PBST served as background. After incubation at 37 • C for 1 h, plates were washed with PBST and then incubated with ABTS (Sigma-Aldrich, St Louis, MO, USA) at 37 • C for 30 min. Absorbance values were read at 405 nm using a SpectraMax M5 microplate reader (Molecular Devices, USA).
Suspending cells were fixed (SCF) on slide for immunofluorescence assay (IFA)
We first used the homemade IFA slide containing PCV2b-infected peripheral blood mononuclear cells (PBMC) which were collected from conventional piglets. Pig sera were detected seropositive for PCV2 by indirect fluorescence antibody (IFA) assay with Porcine Circovirus Type 2 (PCV2) FA Substrate Slide (VMRD, USA), and confirmed as positive for PCV2 DNA by PCR. This new method was invented by Ling-Chu Hung. This approach employed fetal bovine serum to fix suspending cells on glass slide. First, PBMCs were isolated from EDTA treated whole blood samples by density gradient centrifugation. Briefly, three milliliters of EDTA treated blood was diluted 1:1 (v/v) in PBS and layered over Ficoll-Paque Plus (GE Healthcare Bio-Sciences, Uppsala, Sweden). After centrifugation (400g for 30 min at room temperature), the mononuclear cells were recovered from the interface and washed 3 times by wash PBS with centrifugation (100g for 10 min at 4 • C). The PBMCs were resuspended in 0.5 ml fetal bovine serum. Then aliquot 25 l PBMCs per glass slide for cell smear. The slides were air dried at room temperature. Slides were incubated for 10 min at 4 • C with PBS containing 2% paraformaldehyde, and then gently washed 3 times with PBS (5 min per wash). The cells were permeabilized with PBS containing 0.1% Triton X-100 for 3 min at 4 • C. Slides were processed for IFA after washing with PBS.
IFA
The PCV2 FA substrate slides or PBMCs slides were incubated with a 1: 100 dilution of a mouse antiserum, a 1:100 dilution of a pig serum, a 1:50 dilution of an anti-PCV2 mAb 36A9 (Ingenasa, Madrid, Spain) (Rodrıíguez-Carin˜o et al., 2011) or a 1:100 dilution of each test mAb. After incubation at 37 • C for 1 h, slides were gently rinsed briefly in PBS and then soaked for 15 min in PBS at 4 • C. The slides were then incubated at 37 • C with FITC-conjugated goat anti-mouse IgG (subclasses 1 + 2a + 2b + 3, Fc␥), FITC −conjugated goat anti-pig IgG (H + L), or TRITC-conjugated goat anti-mouse IgM (chain) (all from Jackson ImmunoResearch, USA, each antibody minimal cross-reaction to other animals serum protein), or FITCconjugated goat anti-mouse lamda L chain (Novus, Littleton, CO, USA). 30 min after incubation, slide were washed with PBS and then incubated with DAPI (AAT Bioquest, Sunnyvale, CA, USA) at a dilution of 1 in 2300 in PBS for 15 min at room temperature. Samples were mounted under 50% glycerol and observed with a Olympus BX51 fluorescence microscope and SPOT FlEX camera (Diagnostic Instrument, Model 15.2 64MP, USA).
Western blotting
Imumunospecificities of mAbs and sera were assayed against virus-like particle (VLP) of PCV2 (Circoflex, Boehringer Ingelheim, USA) by Western blotting. This VLP of PCV2 (commercial PCV2 vaccine) were separated by Bolt TM Bis-Tris Plus Gel (Invitrogen, Carlsbad, CA, USA). The gels were either stained with FaStain Protein Staining Solution (Yeastern Biotech) or transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore, USA) in Fast Semi-Dry transfer buffer (Thermo, USA) using a Yrdimes Semidry transfer system (Wealtec, Taiwan) at 0.5 mA/cm 2 membrane for 10 min. The membrane was blocked with PBST containing 5% casein hydrolysate for 30 min at 37 • C, and then incubated with anti-C3 mAbs, anti-PCV2 mAb (36A9), anti-VLP of PCV2 rabbit serum, and SPF mouse serum at 37 • C for 2 h, respectively. After three washes in PBST, the membranes were incubated with the appropriate secondary Abs, HRP-conjugated goat anti-rabbit or goat anti-mouse IgG (subclasses 1 + 2a + 2b + 3, Fc ␥ ) or goat anti-mouse IgM, chain (Jackson Immunoresearch, USA) or goat anti-mouse lamda light chain (Novus, USA) according to isotype of mAbs at 37 • C for 1 h, respectively. Wash three times with PBST, 5 min each wash. The membranes were incubated with TOPBIO Enhanced chemiluminescence (ECL) substrate (Topbio, Taiwan) for 5 min. Images were captured in a MultiGel-21-C2 chemiluminescent imaging system (Topbio, Taiwan), and quantified with the ImageJ software.
Epitope mapping
Hybridomas screening and epitope mapping were determined using an indirect ELISA with peptides (as shown in Table 1 ) as coating antigens. Peptides contained the C-terminal sequence of PCV2 capsid protein between residues 195 and 233, associated 10-mer peptides, one peptide (P34) which were conjugated with palmitic acid at Nterminus of peptide C3, and C-truncated derivatives, and negative control peptide (VP2 of Coxsackie virus B5). Ninety-sixwell Maxisorp plates were coated with 100 l of 5 g/ml peptide in bicarbonate buffer and incubated overnight at 4 • C. After three washes in PBST, the plates were blocked with100 l PBST containing 5% casein hydrolysate for 30 min at 37 • C. After washing, hybridoma supernatant were added and plates were again incubated for 2 h at 37 • C. After rinsing three times with PBST, 100 l peroxidase-conjugated goat anti-mouse IgA/IgG/IgM, H/L chain (Novus, USA) for hybridoma screening or 100 l appropriate secondary Abs diluted solution (HRP-conjugated goat anti-mouse IgG (subclasses 1 + 2a + 2b + 3, Fc␥), goat anti-mouse IgM, chain, and goat anti-mouse lamda L chain according to isotype of mAbs) were added, and incubated at 37 • C for another 1 h. The plates were then washed three times, and the colorimetric reaction was developed using 100 l chromogenic substrate ABTS. Following a 30-min incubation away from light, absorbance values were read at 405 nm using a SpectraMax M5 microplate reader.
Amino acid sequence alignment of the Cterminus of the PCV CP
6 different PCV2 strains from different PCV2 genetic clusters have been described (Saha et al., 2012) . Amino acid sequence alignment for residues 167-233 (or 234) in the PCV CP was used in this study. Sequence alignments were made using the T-Coffee multiple-alignment tool (Di Tommaso et al., 2011) and displayed with Jalview Version 2 (Waterhouse et al., 2009 ).
Liquid phase blocking immunoassay (LPBI)
The test is based upon specific blocking of the mAbs in liquid phase by epitope in the test peptide sample. First, we pretested antibody titer of all mAbs with iELISA, and selected proper dilution of mAbs which absorbance values (OD 405 ) larger than 1.5. Added 55 l of the test peptide sample (10 g/ml or 50 g/ml) to 96 wells of the respective polypropylene V-bottom microplate (Nunc, Rochester, NY, USA), and added 55 l volumes of the prediluted mAbs to the appropriate wells. total mixture (final concentration of test peptide sample should be 5 g/ml or 25 g/ml) and were incubated overnight at 4 • C. Next, a 96-well Maxisorp plate (Nunc, Rochester, NY, USA) was coated with 100 l of 5 g/ml C3 in bicarbonate buffer and incubated overnight at 4 • C. After three washes in PBST, the coated plate was blocked with100 l PBST containing 5% casein hydrolysate for 30 min at 37 • C. After rinsing three times with PBST, the peptides/mAbs mixture (100 l) was then transferred to the coated plate for 2 h at 37 • C. After rinsing three times with PBST, 100 l appropriate HRP conjugated secondary Ab diluted solution were added, and incubated at 37 • C for another 1 h. The plate was then washed three times, and the colorimetric reaction was developed using 100 l chromogenic substrate ABTS. Following a 30-min incubation, absorbance values were read at 405 nm using a SpectraMax M5 microplate reader.
Generation of PCV2 capsid protein structural images
The three-dimensional model of PCV2 capsid protein coordinates were obtained from the Protein Data Bank (PDB) entries for the PCV2 capsid protein (PDB: 3R0R) (Khayat et al., 2011) , and images were created using UCSF Chimera version 1.6.2 (Pettersen et al., 2004) from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, USA.
Results
Production and screening of hybridomas
BALB/c mice were immunized with the synthetic peptide (C3). Mice were subsequently euthanized and spleen cells were fused with myeloma cells. Hybridoma supernatants were removed and screened for the presence of C3 specific antibodies by iELISA. From the three fusions, 106 hybridomas were generated which reacted against C3 at first screening. After repeatedly cloning by limiting dilution and screening by iELISA, eight stable hybridomas secreting anti-C3 mAbs were obtained (Table 2) .
Isotyping of mAb
The isotypes of the mAbs were determined using a SBA ClonotypingTM System/HRP according to the manufacturer's instructions. The results are presented in Table 2 . Five hybridomas produced IgG1 mAb and two hybridomas produced IgM mAb. Clones 1H3, 3B2, 4G9, 6B8, and 8A3 secreted the IgG1 subclass of antibody, whereas clones 6D1 and 3E11 secreted the IgM subclass of antibody. No any heavy chain of immunoglobulin was detected in supernatant of clone 6C3. Seven hybridomas produced mAbs with a -light chain of immunoglobulin. Only clone 6C3 produced mAbs with a -light chain of immunoglobulin.
IFA
The specificity of mouse immune serum, pig sera, and mAbs were primary determined by IFA with the PCV2 FA substrate slides according to the manufacturer's manual. Slides were PCV2 virus (strain: T657)-infected swine testicle cells (PT-1) fixed on the surface of Teflon-masked slides. As PCV2-infected PT-1 cells were stained with anti-C3 hyperimmune mouse sera, positive signals were displayed a local distribution in the nucleus, excluding nucleoli (Fig. 1A) . The anti-VLP of PCV2 hyperimmune mouse sera produced dispersing granular and cytoplasmic staining or slight of the shortened peptides were tested for their ability to inhibit the anti-C3 mAbs (dilution of ascites) binding to the C3 (0.5 g/well). The mAb 1H3 (A, B), mAb 3B2 (C, D), mAb 6B8 (E, F), mAb 4G9 (G, H), mAb 8A3 (I, J), mAb 6D1 (K, L), mAb 3E11 (M, N), and mAb 6C3 (O, P) were preincubated with a series of peptides for overnight at 4
• C. The peptides/mAbs mixture was then tested for reactivity against the C3 coated plate. Data represents the mean ± SEM and are representative of three independent assays, with an asterisk indicating significant differences on that dilution. Treatments with different letters have statistically significant differences on that dilution. Statistical significance was calculated using paired Student's t-test. Significant p values are indicated as *p < 0.05. intranuclear staining in PT-1 cells infected with PCV2 (Fig. 1B) . The PCV2-infected pig antiserum produced strong intranuclear and cytoplasmic staining in PT-1 cells infected with PCV2 (Fig. 1C) . However, just only mAb 1H3 produced ambiguous intranuclear staining in PT-1 cells infected with PCV2, mAb 6D1 produced ambiguous cytoplasmic staining in PT-1 cells infected with PCV2, and mAb 3E11 produced intranuclear and cytoplasmic staining in PT-1 cells infected with PCV2 (Supplemental Fig. S1 in the online version at DOI: 10.1016/j.molimm.2017.02.001). In this study, we developed and employed the homemade IFA slide involving PCV2b-infected PBMC which were collected from conventional piglets.
For our homemade PBMCs slides, all wells contain both negative and positive cells (more than 90% positive cells). In Fig. 2C-D Binding curves of the mAbs to minimal epitopes by LPBI. The series of progressive shortened peptides were tested for their ability to inhibit the anti-C3 mAbs binding to the C3 (0.6 g/well). The mAb 1H3 (A), mAb 3B2 (B), and mAb 6B8 (C) were preincubated with a series of peptides for overnight at 4
• C. The peptides/mAbs mixture was then tested for reactivity against the C3 coated plate. Data represents the mean ± SEM and are representative of three independent assays, with an asterisk indicating significant differences on that dilution. Treatments with different letters have statistically significant differences on that dilution. Statistical significance was calculated using paired Student's t-test. Significant p values are indicated as *p < 0.05.
in PBMC (Fig. 2E-F and 2Q-R), similar to that observed in IFA reactivity in positive control. However, mAbs 3B2 displayed positive signals in one of six cells (Fig. 2I-J) . These mAbs produced variable positive intranuclear or cytoplasmic staining pattern in PBMC.
Western blot analysis
The reactivity of the mAbs to the VLP of PCV2 was determined in a Western blot assay. mAbs 3B2 and 36A9 (positive control) gave a specific reaction with proteins of approximately 27 or 30 kDa (Fig. 3) . The band observed corresponds to the expected size of the manufacture's description of patent application (European Application EPO 05108299.8). For mAb 1H3 and 6B8, faint but specific bands were observed at 27 or 30 kDa. Interestingly, mAb 3E11, 6D1 and 6C3, faint but specific bands were observed at 63 kDa approximately. Those mAbs 4G9 and 8A3L showed no reactivity in the Western blot assay. We observed that polyclonal anti-VLP of PCV2 rabbit antibody gave strong reaction with all proteins over 27 kDa. To further confirm specific proteins recognized by antibodies, the VLP of PCV2 loading gel was stained with FaStain Protein Staining Solution. Similar results were obtained, two bands were detected in corresponding to MW of 30 and 63 kDa (Supplemental Fig. 2 in the online version at DOI: 10.1016/j.molimm.2017.02.001).
Epitope mapping
Peptides included the Cterminal sequence of PCV2 CP between residues 195 and 233, associated 10-mer peptides, and C-truncated derivatives, and negative control peptide (P22). Eight mAbs bind the Cterminus of PCV2b-1A/1 B (C3). To determine the binding sites of each mAbs, we performed a peptide scan analysis (Fig. 4A-C) . We successfully mapped the epitopes bound by three of the mAbs. These IgG mAbs (1H3, 3B2, and 6B8) bound to the same linear epitope (P30), including one mAb (1H3) reacted mildly with the PCV2a peptide (P47). However, two non-IgG mAbs (6D1 and 6C3) reacted with these peptides (Fig. 4A ). Our data indicated that two mAbs, 4G9 and 8A3, only reacted with the peptide of immunogen (C3), however, they did not recognized the peptide (P34) which were conjugated with the palmitic acid at Nterminus of C3 (Fig. 4A) . Two non-IgG mAbs (6D1 and 6C3) almost reacted with all peptides ( Fig. 4A-C) , however, they showed minor reaction against the negative control peptide (P22) in ELISA test (Fig. 4A) . To narrow down linear epitopes bound by the mAbs, series of truncated peptides were tested (Fig. 4B-C) . Notably, three IgG mAbs (1H3, 3B2, and 6B8) reacted with five peptides which contained common core peptide (P59, 227 KDPPLNP 233 ). Although mAb 1H3 both reacted with the PCV2b peptide (P30, 225 NLKDPPLNP 233 ) and the PCV2a peptide (P47, 225 NLKDPPLKP 233 ), it neither reacted with the common core peptide (P52, 225 NLKDPPL 231 ), nor with the peptide (P58, 221 FREFNLKDPPLN 232 ) (Fig. 4A-B) . mAbs 3B2 and 6B8 didn't react with the peptide P58, either. To further investigated the epitope specificities of 1H3 and two related mAbs (3B2 and 6B8), we first screened their reactivity against series of truncated peptide (P30, P47, P74) of the Cterminus of PCV2 strains CP (Table 1) between residues 225 and 233 (or 234). Antibody 1H3 reacted with C3, P30, P47, P59, P62, P67, P68 or P73 coated plates (Fig. 4C) , suggested that the minimal amino acid residues of the linear epitope (P62, DPPLNP or P73, LKDPPLKP) recognized by mAb 1H3 was located at position 228-233 of capsid protein of PCV2b-1A/1B or 226-233 of the capsid protein of PCV2a-2A (Fig. 5) . The results also showed that We available mapped their binding residues 227-231 (red residues) onto a single capsid proteins subunit and the crystal structure of PCV2 capsid. The orange residues form the peptide C3 (195-231) were depicted on the ribbon and surface maps of a single capsid proteins subunit. It is coincident that critical binding residues of mAbs (1H3, 3B2, and 6B2) extends toward the capsid exterior (D, E), The three-dimensional model of PCV2 capsid protein coordinates were obtained from the Protein Data Bank (PDB) entries for the PCV2 capsid protein (PDB: 3R0R; Khayat et al., 2011) , and images were created using UCSF Chimera version 1.6.2 (Pettersen et al., 2004 ) from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) the minimal amino acid residues of the linear epitope (P59, KDP-PLNP) recognized by mAbs (3B2 and 6B8) was located at position 227-233 of capsid protein of PCV2b-1A/1B. It was surprised that two peptides (P67 and P68 which contained common core peptide 228 DPPLNPK 234 ) recognized by mAbs (1H3 and 6B8) was located at position 228-234 of capsid protein of PCV2b-1C.
Liquid phase blocking immunoassay (LPBI)
It is conceivable that the binding of mAb 1H3 to C3 coated plate was inhibited by the key peptides (the peptides were recognized by mAbs with iELISA) or the minimal linear epitopes (the minimal amino acid residues of the linear epitope) in the same concentration (5 g/ml just as 0.5 g/well), but it is very unlikely really (Fig. 6A) . The concentration (25 g/ml just as 2.5 g/well) of the minimal linear epitopes (P59 and P62) or the key peptides (P34 and P68) present in the LPBI would thus be moderate or slight inhibition of the interactive binding of mAb 1H3 and C3 (Fig. 6B) . The interactive binding of mAb 1H3 and C3 was stronger than that of mAb 1H3 and all test peptides (including the linear epitopes). The interactive binding of mAb 1H3 and P34 was stronger than that of mAb 1H3 and other test peptides (P62, P59, P68, P67, P73, and P27) and so on. We draws an analogy between the strength of the interactive binding of mAb 1H3 and peptides, just as C3 > P34> P59 (or P62) > P68 > P67, P73 or P27. It is striking that the binding of mAb 3B2 to C3 coated plate was inhibited by the peptides (P62 and P59) in the same concentration (0.5 g/well) (Fig. 6C) . The concentration (2.5 g/well) of the peptides (P62 and P59) present in the LPBI would thus be total inhibition of the binding of mAb 3B2 to C3, and the same concentration of the lipo-peptide (P34) present in the LPBI would thus be moderately inhibited by the binding of mAb 3B2 to C3 (Fig. 6D) . We draws an analogy between the strength of the interactive binding of mAb 3B2 and peptides, just as C3 > P62 > P59 > P34 > P68, P67, P73 or P27. The binding of mAb 6B8 to C3 coated plate was inhibited slightly by peptides (P62, P59, P68, and P34) in the same concentration (0.5 g/well) (Fig. 6E) . The concentration (2.5 g/well) of peptides (P62, P59, P68, P67 and P34) presented in the LPBI inhibited obviously or moderately by the binding of mAb 6B8 to C3 or substantially reduce binding was evident (Fig. 6F) . The interactive binding of mAb 6B8 and C3 was stronger than that of mAb 6B8 and all test peptides (including the linear epitopes). The interactive binding of mAb 6B8 and P62 was stronger than that of mAb 6B8 and other test peptides (P59, P68, P67, P34, P27, and P73). We draws an analogy between the strength of the interactive binding of mAb 6B8 and peptides, just as C3 > P59 (or P62) > P68 > P34 > P67 > P73 or P27. The result indicated that the binding of these mAbs (4G9, 8A3, 6D1, 3E11, and 6C3) to C3 coated plate was not inhibited by any test peptides (P27, P34, P59, P62, P67, P68, and P73) ( Fig. 6G-P) .
To further evaluate which amino acids within the P59 (KDP-PLNP) were particularly important for mAbs (1H3, 3B2, and 6B8) binding, the P59 was shortened and tested for interactive binding to mAbs in LPBI. Our data showed that the concentration (2.5 g/well) of peptides (P62 and P59) present in the LPBI would thus be inhibited obviously by mAbs (1H3, 3B2, and 6B8) binding to the C3 (Fig. 7A-C) . This assay suggested that the core motif (P62, DPPLNP) recognized by mAbs (1H3, 3B2, and 6B8) was located at position 228-233 of capsid protein of PCV2b-1A/1B.
Generation of PCV2 capsid protein structural images
Based on the crystal structure of PCV2 capsid proteins [Protein Data Bank (PDB) codes 3R0R] was reported and using Chimera software to visualize spatially the location of critical binding residues of mAbs (1H3, 3B2, and 6B8). We mapped their binding residues 227-231 onto the crystal structure of PCV2 protein VLP and a single capsid proteins subunit. This epitope were highlight in red (Fig. 8A-E) . The orange and red residues represented the peptide C3 were depicted on the ribbon and surface maps of a single capsid proteins subunit. It is coincident that critical binding residues of mAbs (1H3, 3B2, and 6B8) extends toward the capsid exterior ( Fig. 8D-E) , and the other part of residues of the peptide C3 (orange region) is not accessible on the surface of the VLP, excluding residues 206-209 (Fig. 8E) .
Discussion
According to the previous study (submitted for publication), we designed couples peptides of PCV2 capsid and non-capsid proteins. We tested immunoreactivities of these peptides with sera from PCV2-infected pigs. The ELISA results showed the immunoreactivity of the swine sera and C3 was stronger than that of the swine sera and other peptides (submitted for publication). Since epitopes are the portion of a protein that the adaptive immune receptor recognizes, the identity of the epitope is critical (Abbott et al., 2014; Vita et al., 2015) . In order to search fine epitopes on the peptide C3, we utilized the conjugated C3-KLH to inoculate mice and generate hybridomas. We generated 5 hybridomas producing IgG1 mAb, two hybridomas producing IgM mAb, and one hybridoma producing immunoglobulin without heavy chain.
The positive signal of IFA was shown to depend on antibody binding sites, as the epitope of PCV2 antigen exposure on infected cells. The result suggested that the tertiary or lower form Cterminal sequence (C3) of PCV2 capsid peptide mainly appeared in the nucleus locally, virus-like particles (consisting of 60 CP subunits to form an icosahedron) of PCV2 mainly distributed in the cytoplasm, and all ORF proteins of PCV2 were shown in both cytoplasm and nucleus (submitted for publication). Among this PCV2 virus (strain: T657) and C3 were supposed to have not completely identity at peptide sequences of ORF2 protein. We observed that anti-PCV2a CP peptides (P64) mAbs that produced strong intranuclear positive staining in PK cells infected with this PCV2 strain (unpublished observations). For this reason, just mAb 1H3 reacted weakly with this PCV2 strain (T657), other mAbs (3B2 and 6B8) did not. To address this issue, we used the SCF method to make mononuclear cell IFA slide involving PCV2b infected PBMC cells. Our data showed that mouse antisera and mAbs produced cytoplasmic or intranuclear staining in PBMC. Such variation suggested as a consequence of the transmission of multiple PCV2b strains either around the time of initial infection or sequentially over time. That positive signals of IFA were shown to depend on antibody binding sites and antigen exposure on infected period of cell. These results indicated that both the anti-C3 hyperimmune antisera and all eight mAbs could recognized the PCV2b CP.
Imumunospecificities of mAbs and sera were assayed against VLP of PCV2 (PCV2 vaccine) by Western blotting. The PCV2 vaccine were separated by Bolt TM Bis-Tris Plus Gel (not contain sodium dodecyl sulfate, SDS). These mAbs 1H3, 3B2, 6B8 and 36A9 (positive control) gave a specific reaction with proteins of approximately 27 or 30 kDa. In a similar manner to hyperimmune mouse sera, we observed that anti-PCV2 CP peptides (C3 or P64) mouse sera that gave strong reaction with proteins at 27 or 30 kDa (submitted for publication). Notably, the formation of complexes (dimer, trimer, or tetramer) of PCV2 CP was observed in the Western blots when the sample were detected by polyclonal anti-VLP of PCV2 rabbit antibody.
These IgG mAbs (1H3, 3B2, and 6B8) bound to the same linear epitope (P30), including one mAb (1H3) reacted mildly with the PCV2a peptide (P47) (Fig. 4A) . Our data demonstrated that mAbs (4G9 and 8A3) just recognized the synthetic peptide of C3 with natural folding form, but they did not recognized C3 conjugated with palmitic acid at the N terminal (P34) (Fig. 4A) . Two mAbs (6D1 and 6C3) almost reacted with all peptides, however, they showed minor or no reaction against the negative control peptide (P22) in ELISA test (Fig. 4A ). It's probably that IgM mAbs (6D1) and defective Ig mAb (6C3) have broadly specific binding with associated peptides. For this speculation, these non-IgG mAb could recognized the complexes (dimer) of PCV2 CP in the Western blots (Fig. 3) . Notably, three mAbs (1H3, 3B2, and 6B8) reacted with five peptides which contained common core peptide (P59, 227 KDPPLNP 233 ). Although mAb 1H3 both reacted with the PCV2b peptide (P30, 225 NLKDPPLNP 233 ) and the PCV2a peptide (P47, 225 NLKDPPLKP 233 ) (Fig. 4A) , it neither reacted with the common core peptide (P52, 225 NLKDPPL 231 ) (Fig. 4B ), nor reacted with the peptide (P58, 221 FREFNLKDPPLN 232 ) (Fig. 4B ). These mAbs (3B2 and 6B8) didn't react with the peptide (P58), either. This data show that 233 Pro is not only the last amino acid at the Cterminus of PCV2b-1A/1B capsid protein but also is a vital amino acid of the binding residues of mAbs (1H3, 3B2, and 6B8). This finding is in agreement with the results of a previous study using fine mapping and two mAbs against recombinant dCap protein of PCV2 to confirm the 233 Pro was a crucial and type-specific residue for PCV1 and PCV2 (Shang et al., 2009 ). Noticeably, two peptides (P67 and P68 which contained common core peptide 228 DPPLNPK 234 ) recognized by mAbs (1H3 and 6B8) was located at position 228-234 of capsid protein of PCV2b-1C (Fig. 4C) . It seems that adding a lysine at the Cterminus of P62 (DPPLNP) can enhance affinity with mAbs (1H3 and 6B8) but cannot enhance affinity with mAb (3B2) (Fig. 4C) . These data demonstrated mice were inoculated with Cterminal sequence (C3) of PCV2b −1A/1B capsid protein and that could elicit specific antibodies cross-reacted with PCV2b-1C, particularly the last 7 amino acids at Cterminus of PCV2b-1C capsid protein. Interestingly, PCV2b-1C now appears to be widespread in China and spread globally, and it is proposed a new genotype that could be designated as PCV2d or mutant PCV2b (mPCV2b) (Guo et al., 2010; Constans et al., 2015; Xiao et al., 2015) . Further research should be carried out to deal with these findings.
The LPBI is based upon specific blocking of the mAbs in liquid phase by epitope in the test peptide sample. The C3 (immunogen) is passively adsorbed to polystyrene microwells. After the shortened peptides is allowed to react with the mAbs, the shortened peptides/mAbs mixture is then transferred to an ELISA plate coated with C3. The presence of epitope in the shortened peptides will result in the formation of immune complexes and consequently reduce the amount of free antibody bound by the immobilized C3. After the addition of enzyme-labelled (HRP) anti-mouse Ig (according to isotype of mAbs) conjugate and substrate/chromogen solution, a reduction in color development will be observed when compared to controls containing dilution buffer only. The interactive binding of mAb 1H3 and C3 was stronger than that of mAb 1H3 and all test peptides (including the linear epitopes). This result showed that peptides, P34, P59 (or P62), P68, P67, and P73 could be listed in order of binding affinity with mAb 1H3. Notably, the binding of mAb 1H3 to C3 coated plate was not inhibited by the linear epitope (P73) in the high concentration (2.5 g/well). Although mAb 1H3 reacted with the peptide (P47, 225 NLKDPPLKP 233 or P73, 226 LKDPPLKP 233 ) which were coated on plate in iELISA ( Fig. 4A and  C) , mAb 1H3 and P73 didn't form immune complexes and consequently reduce the amount of free antibody (mAb 1H3) bound by the immobilized C3 in LPBI (Fig. 6B) , implying another factor other than the interactive binding of mAbs and their epitopes. We are going to exploring this possibility with new methods to explain these phenomenon.
Discrepancy, mAbs (3B2 and 6B8) ambiguous reacted with the P62 which were coated on plate by iELISA (Fig. 4C) . Our data demonstrated that the core motif (P62, DPPLNP) within the previous thought minimal linear epitope (P59, KDPPLNP) could be recognized by mAbs (3B2 and 6B8) in the free status by LPBI (Fig. 7C-F) but not be recognized by these mAbs in the fixed form on the plate by iELISA (Fig. 4C) . This result also showed that peptides P62, P59, and P34 could be listed in order of binding affinity with mAb 3B2. It also demonstrated that peptides P59 (or P62), P68, P34, and P67 could be listed in order of binding affinity with mAb 6B8. This phenomenon is a little different from mAb 1H3. This assay suggested that the core motif (P62, DPPLNP) recognized by mAbs (1H3, 3B2, and 6B8) was located at position 228-233 of capsid protein of PCV2b-1A/1B. These critical binding residues of mAbs (1H3, 3B2, and 6B8) just extends toward the capsid exterior (Fig. 8E) .
Conclusions
Taken together, we generate mAbs against C3 and demonstrate a correlation between reactivity to native PCV2 virus and synthetic peptides repertoire. This study also indicated that IgM mAbs and defective Ig mAb have broadly specific binding with associated Cterminal sequence of PCV2 peptides and these non-IgG mAb could recognized the complexes (dimer) of PCV2 CP in the Western blot. It was beyond our expectation, IgG mAbs (1H3 and 6B8) reacted with the core peptide DPPLNPK which was located at position 228-234 of capsid protein of PCV2b-1C. Furthermore, the mAb 1H3 could bind to three minimal linear epitopes (DPPLNP, DPPLNPK, LKDPPLKP), which was located at Cterminus of the capsid protein of PCV2b-1A/1B, PCV2b-1C, and PCV2a-2A, respectively. In the surface view, IgG mAbs (1H3, 3B2 and 6B8) binding residues were located on the exterior of the PCV2 CP. This study confirm that mAbs have pluripotency of binding. It might be an economical way of humoral immune system to recognize the diversity of PCV2 strains.
